Literature DB >> 33628200

NEP-Score Thresholds Predict Survival of Patients With Bronchial Carcinoids.

Irene Gagliardi1, Mario Tarquini1, Maria Rosaria Ambrosio1,2, Elisa Giannetta3, Patricia Borges de Souza1, Roberta Gafà4, Aldo Carnevale5, Paola Franceschetti2, Maria Chiara Zatelli1,2.   

Abstract

Survival prognostic markers are extremely needed to better define therapeutic strategies in patients with bronchial carcinoids (BC). We aim to verify the applicability of the NEP-Score in a homogeneous BC cohort and identify a derivative prognostic marker, the NEP-Score at diagnosis (NEP-D) that does not consider new metastases during follow-up. Sixty-four patients (38 females, and 26 males, mean age at diagnosis 58.9 ± 1.7 years) with BC were retrospectively evaluated. NEP-Score was calculated at the end of follow-up (NEP-T). A derivative score, the NEP-Score at diagnosis (NEP-D) that does not consider new metastases during follow-up, was then assessed. Patients were subdivided according to their living status at the end of follow-up. A NEP-Score threshold was investigated to predict survival. Mean NEP-T and mean NEP-D were significantly lower in live patients at end of follow-up. A NEP-T cut-off >138 significantly predicts survival. Atypical BC relapsed more frequently than Typical BC. Male gender and previous malignancy were negative prognostic factors for survival. We confirmed NEP-Score applicability in BC and NEP-D utility, being the latter a simple, quick, and cheap prognostic score that can help clinicians in decision making. The identified NEP-D threshold can predict NEN aggressiveness and may be used to define the best personalized therapeutic strategy. In this context, a validation study is needed.
Copyright © 2021 Gagliardi, Tarquini, Ambrosio, Giannetta, Borges de Souza, Gafà, Carnevale, Franceschetti and Zatelli.

Entities:  

Keywords:  Delta NEP score; NEP-D; NEP-Score; NEP-T; bronchial neuroendocrine neoplasms; survival

Mesh:

Year:  2021        PMID: 33628200      PMCID: PMC7897663          DOI: 10.3389/fendo.2020.621557

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  33 in total

1.  Outcome and prognostic factors in bronchial carcinoids: a single-center experience.

Authors:  Pier Luigi Filosso; Alberto Oliaro; Enrico Ruffini; Giulia Bora; Paraskevas Lyberis; Sofia Asioli; Luisa Delsedime; Alberto Sandri; Francesco Guerrera
Journal:  J Thorac Oncol       Date:  2013-10       Impact factor: 15.609

2.  Management of bronchial carcinoids: international practice survey among the European Society of Thoracic Surgeons.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Pascal Thomas; Alessandro Brunelli; Eric Lim; Mariano Garcia-Yuste; Hisao Asamura; Konstantinos Papagiannopoulos; Inderpal Sarkaria; Federico Venuta
Journal:  Future Oncol       Date:  2016-06-15       Impact factor: 3.404

3.  The importance of knowledge: what's new in neuroendocrine thoracic tumors.

Authors:  Pier Luigi Filosso
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

4.  Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Authors:  Ivana Sullivan; Gwénaël Le Teuff; Joël Guigay; Caroline Caramella; Amandine Berdelou; Sophie Leboulleux; Désirée Déandréis; Julien Hadoux; Michel Ducreux; Pierre Duvillard; Julien Adam; Jean-Yves Scoazec; Eric Baudin; David Planchard
Journal:  Eur J Cancer       Date:  2017-02-27       Impact factor: 9.162

5.  Survival from rare cancer in adults: a population-based study.

Authors:  Gemma Gatta; Laura Ciccolallo; Ian Kunkler; Riccardo Capocaccia; Franco Berrino; Michel P Coleman; Roberta De Angelis; Jean Faivre; Jean Michel Lutz; Carmen Martinez; Torgil Möller; Risto Sankila
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

Review 6.  Multidisciplinary management of advanced lung neuroendocrine tumors.

Authors:  Pier Luigi Filosso; Piero Ferolla; Francesco Guerrera; Enrico Ruffini; William D Travis; Giulio Rossi; Paolo Olivo Lausi; Alberto Oliaro
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

7.  Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

Authors:  Somer Matar; Anna Malczewska; Kjell Oberg; Lisa Bodei; Harry Aslanian; Anna Lewczuk-Myślicka; Pier Luigi Filosso; Alejandro L Suarez; Agnieszka Kolasińska-Ćwikła; Matteo Roffinella; Beata Kos-Kudła; Jarosław B Ćwikła; Ignat A Drozdov; Mark Kidd; Irvin M Modlin
Journal:  Neuroendocrinology       Date:  2019-04-16       Impact factor: 4.914

8.  Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Nicola Rosario Falco; Pascal Thomas; Mariano Garcia Yuste; Gaetano Rocco; Stefan Welter; Paula Moreno Casado; Erino Angelo Rendina; Federico Venuta; Luca Ampollini; Mario Nosotti; Federico Raveglia; Ottavio Rena; Franco Stella; Valentina Larocca; Francesco Ardissone; Alessandro Brunelli; Stefano Margaritora; William D Travis; Dariusz Sagan; Inderpal Sarkaria; Andrea Evangelista
Journal:  Eur J Cardiothorac Surg       Date:  2019-02-01       Impact factor: 4.191

9.  Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance.

Authors:  Feiran Lou; Inderpal Sarkaria; Catherine Pietanza; William Travis; Mee Sook Roh; Gabriel Sica; David Healy; Valerie Rusch; James Huang
Journal:  Ann Thorac Surg       Date:  2013-07-31       Impact factor: 4.330

10.  A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

Authors:  Marta Peri; Edoardo Botteri; Eleonora Pisa; Filippo De Marinis; Antonio Ungaro; Francesca Spada; Chiara Maria Grana; Roberto Gasparri; Lorenzo Spaggiari; Nicole Romentz; Giuseppe Badalamenti; Antonio Russo; Nicola Fazio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

View more
  1 in total

1.  Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors.

Authors:  Ahmet Bilgehan Sahin; Huseyin Melek; Birol Ocak; Sibel Oyucu Orhan; Buket Erkan; Burcu Caner; Adem Deligonul; Erdem Cubukcu; Ahmet Sami Bayram; Elif Ulker Akyildiz; Turkkan Evrensel
Journal:  Mol Clin Oncol       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.